Sclerostin: therapeutic horizons based upon its actions (Q37974871)

26 August 2017

Sclerostin: therapeutic horizons based upon its actions (English)

1 reference

26 August 2017

2

John P Bilezikian

1 reference

26 August 2017

Aline G Costa

1

1 reference

26 August 2017

1 March 2012

1 reference

Current osteoporosis reports

26 August 2017

1 reference

26 August 2017

10

1 reference

26 August 2017

1

1 reference

26 August 2017

64-72

1 reference

https://scigraph.springernature.com/pub.10.1007/s11914-011-0089-5

26 August 2017

0 references

cites work

Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025.

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0089-5

The use of parathyroid hormone in the treatment of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0089-5

The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0089-5

Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0089-5

Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0089-5

SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0089-5

Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0089-5

Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0089-5

Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0089-5

Sclerostin monoclonal antibody therapy with AMG 785: a potential treatment for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0089-5

Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0089-5

Osteocyte control of bone formation via sclerostin, a novel BMP antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0089-5

Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0089-5

The Wnt signaling pathway and bone metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0089-5

LRP5 and Wnt signaling: a union made for bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0089-5

Regulation of bone mass by Wnt signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0089-5

Regulation of osteoblastogenesis and bone mass by Wnt10b

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0089-5

Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0089-5

Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0089-5

Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0089-5

SOST is a target gene for PTH in bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0089-5

Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0089-5

Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0089-5

Does osteocytic SOST suppression mediate PTH bone anabolism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0089-5

Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0089-5

Regulation of circulating sclerostin levels by sex steroids in women and in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0089-5

Relation of age, gender, and bone mass to circulating sclerostin levels in women and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0089-5

Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0089-5

The natural history of sclerosteosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0089-5

Sclerosteosis in a Spanish male: first report in a person of Mediterranean origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0089-5

Sclerosteosis: neurogenetic and pathophysiologic analysis of an American kinship.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0089-5

A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0089-5

Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0089-5

Bone mineral density in sclerosteosis; affected individuals and gene carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0089-5

Patients with Van Buchem disease, an osteosclerotic genetic disease, have elevated bone formation markers, higher bone density, and greater derived polar moment of inertia than normal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0089-5

Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0089-5

Characterization of the Structural Features and Interactions of Sclerostin: MOLECULAR INSIGHT INTO A KEY REGULATOR OF Wnt-MEDIATED BONE FORMATION

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0089-5

Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0089-5

Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0089-5

Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0089-5

Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0089-5

Glucocorticoid-induced osteoporosis: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0089-5

Glucocorticoid-induced osteoporosis: pathophysiology and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0089-5

A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0089-5

Osteoporosis in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0089-5

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0089-5

A Known SOST Gene Mutation Causes Sclerosteosis in a Familial and an Isolated Case from Brazilian Origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0089-5

Circulating sclerostin in disorders of parathyroid gland function

21 January 2018

1 reference

12 December 2020

Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones

1 reference

12 December 2020

Comparisons of serum sclerostin levels among patients with postmenopausal osteoporosis, primary hyperparathyroidism and osteomalacia

1 reference

12 December 2020

1 reference

12 December 2020

NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, March 7-29, 2000: highlights of the conference

1 reference

12 December 2020

Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover

1 reference

12 December 2020

Sclerosteosis - An autosomal recessive disorder

1 reference

12 December 2020

The syndromic status of sclerosteosis and van Buchem disease.

1 reference

12 December 2020

Increased callus mass and enhanced strength during fracture healing in mice lacking the sclerostin gene

1 reference

12 December 2020

Sclerosteosis: report of a case in a black African man.

1 reference

12 December 2020

Parathyroid hormone as an anabolic therapy for women and men.

1 reference

12 December 2020

Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls

1 reference

12 December 2020

The diagnosis of osteoporosis

1 reference

12 December 2020

Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone

1 reference

12 December 2020

Osteopetrosis with syndactyly; a morphological variant of Albers-Schönberg's disease

1 reference

12 December 2020

An uncommon familial systemic disease of the skeleton: hyperostosis corticalis generalisata familiaris

1 reference

12 December 2020

Sclerostin antibody treatment enhances metaphyseal bone healing in rats

1 reference

12 December 2020

Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss

1 reference

12 December 2020

Guidelines for clinical trials in osteoporosis. A position paper of the European Foundation for Osteoporosis and Bone Disease

1 reference

12 December 2020

Mechanical stimulation in vivo reduces osteocyte expression of sclerostin

1 reference

12 December 2020

Sclerostin antibody treatment enhances bone strength but does not prevent growth retardation in young mice treated with dexamethasone

1 reference

12 December 2020

Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats

1 reference

12 December 2020

Sclerosteosis. A case report

1 reference

12 December 2020

10.1007/S11914-011-0089-5

Identifiers

DOI

1 reference

26 August 2017

1 reference

PubMed ID

22234741